Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases

Next Previous
Drug Profile

Elasomeran - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases

Alternative Names: COVID-19 Vaccine Moderna; Moderna COVID-19 Vaccine; mRNA-1273; mRNA-1273 SARS-CoV-2 vaccine; SARS-CoV-2 RNA vaccine - Moderna Therapeutics; SARS-CoV-2 vaccine - Moderna Therapeutics/National Institute of Allergy and Infectious Diseases; SPIKEVAX; SPIKEVAX-X; SPIKEVAX-XBB.1.5; TAK-919

Latest Information Update: 08 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Moderna Therapeutics; National Institute of Allergy and Infectious Diseases
  • Developer Leiden University Medical Center; Moderna Therapeutics; National Institute of Allergy and Infectious Diseases; Regeneron Pharmaceuticals; Takeda
  • Class COVID-19 vaccines; RNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Marketed COVID 2019 infections
  • Phase III Human papillomavirus infections

Most Recent Events

  • 05 Apr 2024 Arbutus Biopharma and Genevant Sciences issued statement regarding the claim construction ruling in the US District Court for the District of Delaware against Moderna for infringement of US patents in the manufacture and sale of elasomeran
  • 15 Mar 2024 Moderna Therapeutics completes a phase II/III trial in COVID-2019 infections (Prevention, In children, In infants) in USA and Canada (IM) (NCT04796896)
  • 12 Dec 2023 Merck Sharp & Dohme completes a phase III clinical trial in COVID-2019 infections (Prevention, In children) in USA (IM) (NCT05119855) (EudraCT2021-003591-13)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Legal
Back to top